IASO-Innovent Tout Favourable Profile Of BCMA CAR-T
Executive Summary
J&J partner Nanjing Legend and UniCAR developer CARsgen also race for the first China approval for BCMA targeting CAR-T therapy.
You may also be interested in...
Finance Watch: Fundraising Shows Preference For Later-Stage Companies
Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Janssen/Legend’s Cilta-Cel Consistent In Earlier Myeloma, Longer-Term Results
The partners reported initial data at ASH for their BCMA-targeting CAR-T therapy in second-line multiple myeloma that appear consistent with longer-term results and ahead of their main competitor, Bristol’s Abecma.